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Optimizing diagnostic tests 
for persulphate‑induced respiratory diseases
M. H. Foss‑Skiftesvik1,2*, L. Winther3, H. F. Mosbech3, P. S. Skov5, M. S. Opstrup1,3, H. Søsted2, C. Zachariae4, 
J. D. Johansen2 and C. R. Johnsen3
Abstract 
Background: Persulphates from hair bleaching products are considered the major cause of occupational‑rhinitis and 
asthma in hairdressers. The specific inhalation challenge (SIC) is considered ‘reference standard’ for diagnosing per‑
sulphate‑induced asthma and rhinitis; however, the currently validated method of performing SIC with persulphate 
powder is time consuming with a duration of up to 4 days. The value of skin prick tests (SPTs) and histamine release 
tests (HRTs) with persulphates is unknown. The aim of this study was to establish a novel rapid SIC with persulphate 
powder to test for both rhinitis and asthma simultaneously in 1 day. In addition, we assessed the suitability of SPTs 
and HRTs for detecting persulphate‑induced respiratory diseases.
Methods: The study population included 19 hairdressers with a history of work‑related rhinitis and/or asthma symp‑
toms, 12 symptomatic controls (10 with concurrent allergic asthma and rhinitis and two with non‑allergic asthma), and 40 
healthy controls. A previous severe asthmatic reaction and/or anaphylactic reaction to persulphates was considered an 
exclusion criterion for hairdressers. The 19 hairdressers and 12 symptomatic controls had SIC performed with 3 × 5 min 
exposures to potassium persulphate powder in a provocation chamber. All participants, including the 40 healthy controls, 
were subjected also to SPTs and HRTs with three persulphate salts at concentrations of 2–20 % and 0.03–1 %, respectively.
Results: None of the symptomatic controls had a nasal or bronchial response to SIC with potassium persulphate. 
Six hairdressers presented a nasal and two a bronchial response. No severe reactions occurred. No positive SPTs were 
recorded, neither among hairdressers, symptomatic controls, nor healthy controls. All three groups showed nonspe‑
cific non‑IgE mediated histamine release to persulphates in HRT.
Conclusions: The proposed method for performing SIC showed a high specificity for detecting persulphate‑induced 
asthma and rhinitis. The rapid SIC was able to produce positive nasal and bronchial responses in symptomatic 
hairdressers without any severe reactions occurring. SPTs and HRTs cannot predict asthma or rhinitis caused by 
persulphates.
Keywords: Specific inhalation challenge, Persulphates, Persulphate salts, Histamine release test, Skin prick tests, 
Occupational asthma, Occupational rhinitis
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(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Persulphates are low-molecular weight chemicals 
(<10  kDA) with strong oxidizing properties and wide 
application in hair bleaching products. They are also 
found in dental prosthesis cleaners, food starch, paper 
and cellophane, as a reducing agent in photography, and 
as etching solution for printed circuit boards [1]. Persul-
phates can induce immediate and delayed reactions, such 
as contact dermatitis, contact urticaria, asthma, rhini-
tis, and anaphylaxis [2–6]. Reported cases of immediate 
type reaction caused by persulphates are predominantly 
among hairdressers, but also workers producing persul-
phates [7, 8] and consumers of hair bleaching products 
[3, 9] have been reported to react.
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As with most low-molecular weight agents, the mecha-
nism by which persulphates induce immediate reactions 
is not fully understood. Immunoglobulin E (IgE) [4, 8, 
10], T-cells [11, 12], and oxidative events have been pro-
posed to contribute to the development of persulphate-
induced asthma and rhinitis [13].
When assessing a patient with possible persulphate-
induced rhinitis or asthma, various tests can be con-
sidered. Several studies describe the use of skin prick 
tests (SPTs) [10, 14, 15]; however, validation and stand-
ardization are lacking. Only one study addressed the use 
of histamine release test (HRT) [16] and results were 
inconclusive.
The specific inhalation challenge (SIC) is held as ‘reference 
standard’ for diagnosing occupational-rhinitis and asthma 
[17]. SIC with persulphate has been performed with a realis-
tic approach attempting to reproduce conditions in the hair-
dressing salon [18–20]. Typically, mixtures of persulphate 
powder and lactose powder [20], or bleaching powder and 
hydrogen peroxide [21] are tipped from one tray to another 
inside a specially designed provocation chamber. The test 
has also been performed by administering an aqueous per-
sulphate solution with a nebulizer and by spraying the solu-
tion directly into the nose when examining asthma [22, 23] 
and rhinitis [12], respectively. The SIC performed with per-
sulphate in the realistic approach has previously been vali-
dated [20]. In this validated approach, the patient is exposed 
to a mixture of persulphate powder and lactose powder. 
The exposure is performed step-wise with increasing doses 
of persulphate during four consecutive days. The maximal 
exposure on the fourth day is 30 g of potassium persulphate 
for 10 min. A sensitivity of 100 % and a specificity of 87.5 % 
for diagnosing persulphate-induced asthma were reported. 
A disadvantage of this approach is, that it is very time con-
suming for both investigator and patient.
The aim of our study was, with a focus on Munoz’ vali-
dated method, to establish a new realistic approach rapid 
SIC performed with potassium persulphate to test for both 
rhinitis and asthma simultaneously in 1 day. Instead of using 
the step-wise approach over several days, we exposed the 
patients to 30 g of potassium persulphate on the first day for 
3 × 5 min. Instead of the typical tipping method, we used a 
new stirring method in order to obtain a more reproducible 
exposure. In addition, we assessed the potential for diagnos-
ing persulphate-induced asthma and rhinitis by SPTs and 
HRTs using three different persulphates (ammonium per-
sulphate, potassium persulphate and sodium persulphate) in 
concentrations from 2–20 and 0.03–1 %, respectively.
Methods
The study was performed as a clinical single-blinded 
case–control study between February 2014 and May 
2016.
Hairdressers
Hairdressers with work-related respiratory symptoms 
who had either contacted the hot-line of the Research 
Center for Hairdressers and Beauticians or were refer-
eed to our unit for suspected occupational asthma and/
or rhinitis were eligible for inclusion in this study. Hair-
dressers with a history of severe asthmatic reactions and/
or anaphylactic reactions to hair bleaching products 
were excluded. Standardized interviews were employed 
to obtain a detailed medical and occupational history, as 
well as records of atopic diseases and smoking. Respira-
tory symptoms suggestive of asthma and rhinitis were 
assessed and their association with exposure to persul-
phates and other hairdressing chemicals was explored. 
A positive stop/resume test was defined as respiratory 
symptoms improving after periods away from work and 
worsening at the workplace [24]. A physical examination 
that included rhinoscopy was performed to exclude nasal 
conditions mimicking rhinitis.
Symptomatic controls
Individuals with a history of asthma and rhinitis without 
known sensitization or exposure to persulphates were 
recruited among patients in our unit and through an 
advertisement on a website for research subjects.
Healthy controls
For the SPT and HRT with persulphates we recruited a 
group of healthy controls without known asthma, rhini-
tis, or urticaria.
Prior to any clinical tests, inhaled corticosteroids 
were discontinued for 2 weeks, oral antihistamine and 
nasal corticosteroids for 72  h, long-acting beta2-ago-
nist and leukotriene receptor antagonists for 48 h, and 
short-acting beta2-agonist for 8  h. The following were 
considered exclusion criteria: unstable asthma dur-
ing the last 3  months before inclusion, regular use of 
oral corticosteroids, baseline forced expiratory volume 
in 1 s (FEV1) ≤70 % of predicted normal value, recent 
(<4 weeks) respiratory tract infection, chronic obstruc-
tive pulmonary disease, severe hypertension, immuno-
logical diseases, pregnancy or unstable cardiovascular 
diseases.
Immunologic tests
SPTs were performed in duplicate with 10 common 
aeroallergens (Soluprick SQ®; ALK-Abelló, Hørsholm, 
Denmark), latex, and chlorhexidine digluconate (5  mg/
mL). Negative (diluent) and positive (histamine 10  mg/
mL) controls were also included. A positive reaction was 
defined by a wheal with a diameter ≥3 mm. The SPT was 
only considered to be valid when the positive control was 
positive and the negative control was negative. Atopy was 
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defined as a positive SPT reaction to one or more of the 
common allergens.
In addition, SPTs were performed with freshly pre-
pared solutions of ammonium persulphate (ACS reagent 
≥98.0  %, CAS 7727-54.0), potassium persulphate (ACS 
reagent, ≥99.0  %, CAS 7727-21-1), and sodium persul-
phate (purum p.a., ≥99.0 %, CAS 7775-27-1); all Sigma-
Aldrich, St. Louis, MO, USA. The persulphates were 
dissolved in physiologic saline solution. Ammonium and 
sodium persulphate were prepared at 2, 5, 7.5, 10 and 
20 (wt/vol). Potassium persulphate was used at 2, 5, and 
7.5 (wt/vol), as it was insoluble at higher concentrations. 
The solutions’ pH ranged from 1.45 to 5. First, the lowest 
three concentrations of the persulphates solutions were 
applied. If no reaction occurred within 15 min, 10 % solu-
tion was applied. Finally, if no reaction occurred again, 
the test was performed with the 20 % solution. Reactions 
were recorded after 15 and 30 min.
Heparinized blood (5 mL) for HRT was collected at and 
sent to RefLab ApS (Copenhagen, Denmark) according to 
standard procedures. Blood samples were stored at room 
temperature for a maximum of 6  h prior to analysis. 
Persulphate solutions were prepared daily and tested at 
concentrations of 0.03, 0.06, 0.125, 0.25, 0.5 and 1.0 (wt/
vol) in duplicates. Briefly, 25 µL aliquots were incubated 
with 25 µL persulphate dilutions at 37 °C for 1 h. During 
incubation, the released histamine bound to a glass fiber 
coated microtitre plate and was detected fluorometrically 
after coupling to o-phthaldialdehyde [25]. Positive reac-
tions were categorized according to the lowest concen-
tration producing significant histamine release (10  ng 
histamine/mL blood). If no histamine was released, the 
result was categorized as negative.
Finally, whole blood was collected, serum was sepa-
rated and stored at −20 °C until total IgE was measured 
by the ImmunoCap® assay (Thermo Fisher Scientific, 
Waltham, MA, USA).
Lung function tests
Hairdressers and symptomatic controls had relevant 
asthma medication discontinued prior to the perfor-
mance of any lung function tests. Spirometry, including 
reversibility test and methacholine challenge was per-
formed for each hairdresser and control 2–3 days before 
SIC.
Forced expiratory flow in the first second (FEV1) and 
forced vital capacity (FVC) within 2 standard devia-
tions (SD) of predicted normal values were considered 
normal. The reversibility test was deemed positive if 
FEV1 increased by ≥12 % or >200 ml upon inhalation of 
β2-agonist. Bronchial hyperresponsiveness (BHR) was 
assessed by the bronchial provocation test with metha-
choline. The provocative dose of methacholine producing 
a 20 % fall in FEV1 (PD20) was expressed in micrograms.
After spirometry, fractional exhaled nitric oxide 
(FeNO) was measured with a DENOX 88 analyzer (ECO 
MEDICS AG, Duernten Switzerland) and was considered 
elevated at ≥25 ppb [26].
SIC with persulphate
SIC was performed on an outpatient basis. On a separate 
control day, SIC was performed with 50 g d-lactose mono-
hydrate (Sigma-Aldrich). In the absence of a bronchial- 
and nasal response during the following 24  h, subjects 
were exposed to a mixture of 30 g potassium persulphate 
and 20  g lactose powder. The participants, but not the 
investigator, were blind to the nature of the challenges.
During exposure, participant sat at a table inside a 
provocation chamber (2.1 m × 2.2 m × 2.3 m) at ambi-
ent temperature and humidity. Fresh air was supplied at 
0.5/h through a high efficiency particulate air and carbon 
filters. Test substances were contained in a 1-L Erlen-
meyer flask (Schott, Mainz, Germany), placed 30  cm 
from the subjects’ face on a magnetic stirrer (IKAMAG® 
RCT basic; IKA, Staufen, Germany), and swirled in the 
air by stirring the magnet (length: 7  cm) at 810  rpm. 
Maximal exposure consisted of 3 × 5 min, with 20-min 
intervals in between. During pauses and after maximal 
exposure was reached, participants were removed from 
the provocation chamber. Exposure was discontinued if 
the patient developed a significant bronchial response 
before maximal exposure was reached. Monitoring for a 
bronchial and nasal response was performed at baseline; 
in between each exposure; 15, 30, and 60 min after expo-
sure; and hourly thereafter until sleep. Participants were 
monitored in the hospital during the first 8 h; thereafter, 
they performed self-measurements of FEV1 and nasal 
symptoms at home until sleep and again the following 
morning when waking up.
Quantification of potassium persulphate during SIC
To assess the reproducibility of the stirring method, the 
amount of potassium persulphate in the provocation 
chamber was quantified during three challenges on three 
separate days. Particles sized 10–300 nm and 0.1–10 µm 
were counted using a NanoTracer PNT800 (Philips Elec-
tronics, Eindhoven, The Netherlands) and a Dust Trak™ 
Aerosol Monitor Model 8520 (TSI, Shoreview, MN, 
USA), respectively, placed 30  cm away from the Erlen-
meyer flask.
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Evaluation of bronchial response
Airway obstruction was assessed by FEV1 using a porta-
ble asthma monitor (AM1; Jaeger, Hoechberg, Germany). 
A sustained ≥15 % decrease in FEV1 from baseline was 
considered a positive result for asthma, provided that 
fluctuations in FEV1 were ≤10 % on the control day [27].
Evaluation of nasal response
Rhinitis was measured using three tests: Linder’s symp-
toms score scale, changes in nasal cavity volume, and 
anterior rhinoscopy. SIC with persulphate was consid-
ered positive for rhinitis if ≥2 tests were positive and the 
participant had <2 positive tests on the control day.
Linder’s symptoms score scale
Subjective symptoms of rhinoconjunctivitis were scored 
according to Linder’s symptoms score scale [28, 29]. Par-
ticipants rated sneezing, rhinorrhea, and nasal conges-
tion from 0 to 3. Ocular symptoms scored 1 point, and 
itchiness of the nose, ears or palate scored 1 point for 
each location with itch. An increase of ≥3 points from 
baseline was considered a positive result.
Changes in nasal cavity volume
Swelling of the nasal mucosa was assessed by means of 
acoustic rhinometry using a Rhinoscan® SRE 2000 (Rhi-
noMetrics A/S, Lynge, Denmark) as previously described 
[30]. Participant had acclimatized for 20 min before base-
line measurements were performed. Total nasal volume 
(TNV) was measured at 2–6 cm from the nares. A ≥25 % 
fall in TNV after exposure was considered a positive 
result [28].
Scoring by anterior rhinoscopy
Anterior rhinoscopy was performed and rhinorrhea and 
nasal congestion were scored separately according to the 
method proposed by Hytonen [31]. A change in nasal 
status score of ≥4 points between baseline and exposure 
was considered a positive response [31].
Statistical analysis
Data were analyzed using SPSS 22.0 for Windows (SPSS 
Inc., Chicago, IL, USA). Results for categorical variables 
are presented as numbers and frequencies, and are com-
pared by the Fischer’s exact test. P values ≤0.05 were 
considered statistically significant (two-tailed tests). Con-
tinuous variables were compared with the Mann–Whit-
ney U test and expressed as means ± SDs.
Results
Hairdressers
A total of 20 hairdressers were considered eligible for 
inclusion; one was excluded because of unstable asthma. 
All were female and the mean age was 31 years (Table 1). 
Six hairdressers were atopic and three had atopic derma-
titis. FeNo was elevated in three, FEV1/FVC was reduced 
in three, and five showed bronchial hyperresponsiveness 
in the methacholine challenge. Seven hairdressers used 
asthma medication and six used rhinoconjunctivitis med-
ication (Table 1). When asked about work-related symp-
toms, one hairdressers reported asthmatic symptoms (≥2 
of the following: wheeze, cough, shortness of breath or 
hoarseness), one reported rhinitis symptoms (≥1 of the 
following: nasal itching, runny nose, blocked nose, itchy 
and watery eyes), and 17 reported both asthmatic and 
rhinitis symptoms. All 19 hairdressers reported symp-
toms in relation to hair bleaching and 11 (58  %) admit-
ted that their symptoms could also be provoked by other 
hairdressing products such as hair dyes, hairsprays, per-
manent wave solutions, and perfume (Table 1).
Symptomatic controls
A total of 14 symptomatic controls were eligible for inclu-
sion in the study; two had to be excluded due to unstable 
asthma leaving ten with concomitant allergic asthma and 
rhinitis and 2 with non-allergic asthma. The mean age 
was 21  years and 58  % were female (Table  1). Half had 
atopic dermatitis. Elevated FeNO was detected in 42 %, 
FEV1/FVC was reduced in three, and the methacholine 
challenge was positive in seven. All used asthma medica-
tion, whilst only the ten with concomitant allergic rhinitis 
used rhinitis medication (Table 1).
Healthy controls
A total of 40 healthy participants had SPT and HRT with 
persulphates performed.
Results of SIC
None of the participants reacted to placebo. None of the 
symptomatic controls developed a nasal or bronchial 
response when exposed to potassium persulphate in SIC. 
A total of six (32 %) hairdressers showed a positive reac-
tion to SIC with persulphate; four had a nasal response, 
and two had a combined bronchial and nasal response 
(Table 2). 
All hairdressers with a positive SIC, reported a posi-
tive stop/resume test, whereby their symptoms sub-
sided in periods away from work and deteriorated again 
when returning to work. They had all been exposed to 
hairdressing for ≥6  months before developing work-
related respiratory symptoms. The typical time inter-
val between initiating work with bleaching products 
and the appearance of symptoms, was minutes (n = 3), 
hours (n = 2), or it could not be defined (n = 1). Half 
of the hairdressers had discontinued their work, and 
hence were no longer exposed to persulphates on a 
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daily basis. The nasal responses to SIC began within 
minutes (n = 2), after 1 h (n = 3), and after 3 h (n = 1). 
The two hairdressers reacting with bronchoconstriction 
did so after 3 h and 8 h, respectively. The characteris-
tics of hairdressers with negative SICs are presented in 
Table 3. 
Table 1 Main characteristics of participants
SD standard deviation, BMI body mass index, SABA short‑acting beta2‑agonists, LABA long‑acting beta2‑agonists, ICS inhaled corticosteroids, LTRA leukotriene receptor 
antagonists, INS intra‑nasal steroid
a Defined as 1 ≥positive SPT or 1 ≥positive specific IgE to common inhalant allergens
α Comparing hairdressers with controls
Hairdressers  
(n = 19)
Symptomatic  
controls (n = 12)
Healthy  
controls (n = 40)
P valueα
Mean age, years (SD) 31 (10.5) 21 (2.6) 35 (12.9) 0.002
BMI, mean (SD) 22.5 (3.8) 22.4 (3.4) 24.7 (4.3) 1.000
Sex (% female) 19 (100) 7 (58) 43 0.02
Smoking status, n (%)
 Smoker 7 (37) 5 (42) – 0.79
 Never smoker 12 (63) 7 (58) –
Atopic dermatitis, n (%) 3 (16) 6 (50) 0 (0) 0.06
Total IgE, mean (SD) 58.3 (76) 156.5 (202) 0.22
Atopya (%) 6 (32) 10 (83) 0.009
FeNO ≥ 25 ppb, n (%) 3 (16) 5 (42) 0.20
FeNO ≥ 50 ppb, n (%) 1 (5.2) 3 (25)
Lung function, mean (SD)
 % FEV1 101.7 (9.7) 106.6 (14.8) 0.48
 % FVC 105.3 (8.7) 116.8 (14.1) 0.025
 FEV1/FVC 84.8 (7.6) 78.9 (6.6) 0.43
Methacholine test
 BHR, n (%) 5 (26) 7 (58) 0.13
Asthma medication, n (%)
 None 12 (63) 0 (0)
 SABA 3 (16) 7 (58)
 SABA + low dose ICS 1 (5) 3 (25)
 SABA + medium dose ICS 1 (5) 2 (17)
 SABA + LABA/ICS 1 (5) 0 (0)
 SABA + LTRA 1 (5) 0 (0)
Rhinitis medication, n (%)
 None 13 (68) 2 (17)
 OA 2 (11) 8 (67)
 INS 1 (5) 1 (8)
 OA + INS 2 (11) 1 (8)
 OA + antihistamine eye drops 1 (5) 0 (0)
Work‑related symptoms, n (%)
 Rhinitis symptoms 1 (5) –
 Asthma symptoms 1 (5) –
 Both 17 (90) –
Trigger of symptoms, n (%)
 Bleaching products 19 (100) –
 Hair dye 9 (49) –
 Hair spray 4 (21) –
 Permanent solution 3 (16) –
 Perfume 3 (16) –
Positive stop/resume test, n (%) 16 (84) –
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Quantification of potassium persulphate
Before exposure, the amount of particles sized 0.1–10 µm 
inside the provocation chamber ranged from 7 to 18 µg/
m3 and the number of ultra-fine particles was 347–1260/
cm3. No additional ultrafine particles were detected dur-
ing a 3 × 5 min exposure to 50 g pure potassium persul-
phate in the Erlenmeyer flask.
The mean amount of particles sized 0.1–10 µm meas-
ured during a 5-min exposure to a mixture of 30  g 
potassium persulphate and 20  g lactose ranged from 
0.25–0.57  mg/m3 and the proportion of potassium per-
sulphate to lactose powder in the flask was 3:2. Thus, the 
estimated concentration of potassium persulphate in the 
air during a 5-min exposure was 150–340 µg/m3 with a 
mean of 240  µg/m3 and a standard deviation of 0.6  µg/
m3. During the 20-min pause in between exposures, the 
amount of particles in the air returned to baseline values.
SPT results
In two hairdressers, the negative control was positive due 
to dermographism and therefore their SPTs could not be 
evaluated (Table 4). All participants reacted to the positive 
control (histamine), whilst none were positive to latex, chlo-
rhexidine, or any of the three tested persulphates (Table 4).
Results of HRT with persulphates
Of the six hairdressers with a positive SIC, four (66.7 %) 
did not react to HRT with potassium persulphate or 
sodium persulphate at any of the tested concentra-
tions. In contrast, all six hairdressers with positive SICs 
released histamine in response to ammonium persul-
phate at concentrations ranging from 0.063 to 1 %. So did 
also 96.2 % of symptomatic controls and healthy controls. 
For all three persulphates, the lowest concentration pro-
ducing histamine release in the controls and healthy con-
trols was 0.125 %, whilst some of the hairdressers reacted 
to concentrations of 0.06  %. None of the participants 
showed histamine release to any of the persulphates in 
concentration of 0.031 %.
Discussion
SIC
In this study, we aimed at improving the currently vali-
dated SIC with persulphate. The improvements consisted 
Table 2 Characteristics of hairdressers with a positive specific inhalation challenge
y years, WRAS work‑related asthma symptoms, WRRS work‑related rhinitis symptoms, MCh methacholine challenge, FeNO fractional exhaled nitrogen oxide (increased 
values in italics), T-IgE total immunoglobulin E, HRT histamine release test, PP potassium persulphate, AP ammonium persulphate, SP sodium persulphate, SIC specific 
inhalation challenge, N negative, P positive, CE currently exposed, R rhinitis, A asthma
a Defined as ≥1 positive SPT to common inhalant allergens
ID Age (y) WRAS WRRS Stop/ 
resume test
Duration 
of exposure 
before symptoms 
(y)
Time from expo-
sure to symptom
Time since last 
exposure to per-
sulphates (y)
Baseline FEV1/
FVC (% of pred.)
MCh PD20 (µg)
2 21 + + P 5 Within hours CE 87 (103 %) 330
5 29 + + P 11 Not definable CE 86.7 (104 %) N
8 32 + + P 1.5 Within minutes 8 85.5 (103 %) 346
10 22 + + P 4–5 Within hours CE 80.6 (96 %) N
16 23 + + P 0.5–1 Within minutes 2 85.4 (101 %)
Rever: 12 %
N
19 23 + + P 0.5–1 Within minutes 1/3 94.9 (113 %) N
ID Age (y) FeNO (ppb) T-IgE (kU/L) Atopya HRT PP  
(mg/mL)
HRT SP  
(mg/mL)
HRT AP  
(mg/mL)
SIC response Classification of SIC 
response
2 21 6.3 73.2 No N N 2.5 R
A
4 and 8 after 3rd expo‑
sure (late reaction)
5 29 6.2 8.7 Yes N 10.0 10.0 R 1 h after 3rd exposure 
(immediate reaction)
8 32 31.2 46.4 Yes N N 5.0 R 1 h after 3rd exposure 
(immediate reaction)
10 22 7.4 26.6 No N N 10.0 R
A
1 and 3 h after 3rd 
exposure (immediate 
reaction/late reaction)
16 23 13.0 39.8 Yes 10.0 2.5 1.25 R After 2nd exposure 
(immediate reaction)
19 23 16.9 63.6 Yes 0.63 – 0.63 R After 3rd exposure 
(immediate reaction)
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of: a more rapid approach; using the “stirring method” 
instead of the “tipping method”; and assessing not only 
asthma but also rhinitis.
When Munoz et al. validated the realistic method [20], 
repeated exposures on consecutive days were performed 
with a mixture of potassium persulphate and 150 g lac-
tose using the tipping method. The duration of the expo-
sure was 10  min each day, and the dose of potassium 
persulphate was increased from 5 to 30  g over 4  days 
until a positive reaction occurred. The patient was hospi-
talized during the entire procedure. The method proved 
safe and a sensitivity of 100 % and a specificity of 87.5 % 
for diagnosing occupational asthma were reported.
In our method, we skipped the first 3  days with low 
exposure, and went straight to exposing the patient to 
30 g of potassium persulphate. Instead of 10 min expo-
sure we performed 15 min exposure. To reduce the risk 
of adverse reaction, exposure was performed step-wise; 
5  min at a time with 20  min pauses in between, and 
severe asthmatic reactions and/or anaphylactic reac-
tions to bleaching products were considered exclusion 
criteria.
Table 3 Characteristics of hairdressers with a negative specific inhalation challenge
y years, WRAS work‑related asthma symptoms, WRRS work‑related rhinitis symptoms, MCh methacholine challenge, FeNO fractional exhaled nitrogen oxide (increased 
values in italics), T-IgE total immunoglobulin E, HRT histamine release test, PP potassium persulphate, AP ammonium persulphate, SP sodium persulphate, SIC specific 
inhalation challenge, N negative, P positive, CE currently exposed, D dermographism, R rhinitis, A asthma
a Defined as ≥1 positive SPT to common inhalant allergens
ID Age (y) WRAS WRRS Stop/resume 
test
Duration of exposure 
before symptoms (y)
Time from exposure 
to symptoms
Time since last 
exposure to persul-
phates (y)
Baseline FEV1/FVC 
(% of pred.)
1 52 + + N 3 Within hours 5 86 (109 %)
3 45 + + P 20 Within hours CE 83 (104 %)
4 49 + + P 28 Within minutes CE 65 (81 %)
Rever: 2.9 %
6 30 – + P 10 Within minutes 3 81 (97 %)
7 27 + + P 1 Not definable 1 84.9 (103.3 %)
9 20 + + P 1 Within minutes CE 98 (116 %)
11 43 + + P 20 Within hours CE 83 (103 %)
12 23 + + N 3 Within hours CE 74 (88 %)
Rever: 12 %
13 46 + – N 2 Not definable 3 83 (103 %)
14 27 + + P 7 Within minutes CE 83 (99 %)
15 31 + + P 4 Within minutes 1/2 75 (90 %)
Rever: 7.8 %
17 20 + + P 4 Not definable 1/6 91 (108 %)
18 29 + + P 8 Within hours CE 91 (109 %)
ID Age (y) MCh PD20  
(µg)
FeNO  
(ppb)
T-IgE  
(kU/L)
Atopya HRT PP  
(mg/mL)
HRT SP  
(mg/mL)
HRT AP 
(mg/
mL)
1 52 N 25 3.6 No 1.25 0.63 1.25
3 45 N 9.9 6.7 No N 5.0 2.5
4 49 N 16.0 2.2 No 10.0 10.0 5.0
6 30 400 64.1 155 No N 10.0 5.0
7 27 N 19.3 127 D N 5.0 2.5
9 20 N 6.6 <2 No N 10.0 5.0
11 43 N 7.1 22.5 No N 10.0 5.0
12 23 N 21.8 122 No 10.0 5.0 2.5
13 46 626 12.1 35.4 No N 5.0 1.25
14 27 N 11.8 3.7 No N 10.0 5.0
15 31 720 9.0 308 D 5.0 2.5 1.25
17 20 N 9.0 4.3 No 10.0 2.5 2.5
18 29 N 19.7 58.3 No N N N
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Given that none of the symptomatic controls with 
allergic asthma and rhinitis reacted to SIC, it seems 
that the proposed method has a high specificity for 
persulphate-induced asthma and rhinitis. In this group 
of hairdressers, SIC produced a nasal response in 33  % 
(6/18 with work-related rhinitis symptoms) and a bron-
chial response in 11  % (2/18 with work-related asthma 
symptoms).
We registered no adverse events or severe asthmatic 
reactions although our exposure was higher than Munoz’ 
on the fourth day. Hence, it seems that the rapid method 
is safe when tested in patients without a history of severe 
asthmatic reactions or anaphylactic reactions to bleach-
ing products.
We have several reasons for using the level of exposure 
we did. Firstly, we chose 3  ×  5  min exposure to better 
mimic the hairdressers’ exposure during a typical work-
ing day. Since hairdressers are mainly exposed to persul-
phates when they mix bleaching powder with hydrogen 
peroxide [32], we wanted to mimic this process. We esti-
mated that a typical hairdressers performs this process 
three times a day. Secondly, the ratio of persulphate to 
lactose powder was changed as to better mimic the level 
hairdressers are exposed to in their daily practice. During 
mixing of the paste that is applied to the clients hair, 
20–80  g bleaching powder [33], containing up to 60  % 
persulphate (12–48  g) [1], is typically used. We there-
fore used a ratio of persulphate to lactose powder of 3:2 
(30 g persulphate:20 g lactose powder). To obtain a more 
uniform and reproducible exposure, we used a magnetic 
stirrer. In our study, the participants were exposed to lev-
els of up to 0.34  mg/m3 for 3 ×  5  min during SIC. The 
permissible threshold limit value of exposure to potas-
sium persulphate, as defined by the Occupational Safety 
and Health Administration in the United States, is a time 
weighted average (TWA) of 0.1  mg/m3 during a typical 
working day of 8  h. According to the excursion limit of 
potassium persulphate, the TWA should not be exceeded 
more than 3 times for no longer than 30  min during a 
working day. Hence, the TWA was exceeded during our 
exposure, but the excursion limit was respected.
A limitation of our approach is that the patients were 
sent home after 8  h of observation in the clinic. This is 
convenient for the patient, but it introduces a potential 
bias. If the patient develops a positive nasal or bronchial 
response during this period at home, it is difficult to inter-
pret whether the response was caused by exposure to per-
sulphates or by exposure to other allergens encountered 
outside the hospital. However, in our study, all hairdress-
ers reacted whilst being monitored in our department, so 
it is unlikely that this is a problem in our results.
Another limitation of our study is that the included 
hairdressers were merely under suspicion of having occu-
pational asthma and rhinitis, but they were not clear-
cut cases, which explains why only some hairdressers 
had a positive reaction to SIC. Firstly, they did not have 
serial peak flow measurement at and away from work 
performed prior to inclusion. If we had included only 
patient with a peak flow pattern suggestive of occupa-
tional asthma it might have improved the sensitivity of 
the test for detecting persulphate-induced asthma. Sec-
ondly, many had normal findings in spirometry, FeNO, 
and the methacholine challenge suggesting that they did 
not in fact have asthma although they reported asthmatic 
symptoms. Third, although persulphates are considered 
the major cause of occupational asthma and rhinitis 
in hairdressers [34] more than half reported that their 
work-related respiratory symptoms could also be pro-
voked by other hairdressing products suggesting that 
their respiratory symptoms were not merely caused by 
persulphates. Also, some of the hairdressers had not been 
active hairdressers for several years and therefore were 
not still exposed to persulphates meaning that they could 
have lost airway responsiveness. Taken together, several 
factors exist that could explain why not all hairdressers 
reacted to the SIC and consequently the sensitivity of our 
approach cannot be determined.
Table 4 Results from skin prick tests
p positive, n negative
Hairdressers 
(n = 19)
Symptomatic  
controls (n = 12)
Healthy 
controls 
(n = 40)
Positive control (p/n) 19/0 12/0 40/0
Negative control (p/n) 2/17 0/12 0/40
Potassium persul‑
phate (p/n) Conc. 
(%)
0/17 0/12 0/40
 2 – – –
 5 – – –
 7.5 – – –
Ammonium persul‑
phate (p/n) Conc. 
(%)
0/17 0/12 0/40
 2 – – –
 5 – – –
 7.5 – – –
 10 – – –
 20 – – –
Sodium persulphate 
(p/n) Conc.  (%)
0/17 0/12 0/40
 2 – – –
 5 – – –
 7.5 – – –
 10 – – –
 20 – – –
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HRT and SPTs with persulphate salts
This is the first study, to the best of our knowledge, to 
report results of HRT with persulphates. We found that 
persulphates, especially ammonium persulphate, induced 
non-IgE-mediated histamine release in both hairdress-
ers and controls. Additionally, most of the SIC-positive 
hairdressers did not show histamine release. Ammonium 
persulphate has recently shown to have oxidative activ-
ity capable of promoting degranulation of human mast 
cells and basophils [13]. Thus, persulphates stimulate 
nonspecific non-IgE-mediated histamine release even in 
individuals without symptoms of persulphate-induced 
respiratory diseases, voiding the use of HRT to document 
asthma or rhinitis caused by persulphates.
We performed SPTs in duplicate with all three persul-
phates simultaneously, at concentrations as high as 20 %. 
To our knowledge, this has not been done before. We did 
not register any positive SPTs with persulphates in any of 
the participants, although all responded positively to the 
histamine control. Given the high persulphate concentra-
tions applied, lack of positive reactions does not seem to 
be caused by using excessively low dosage. In addition, by 
testing all three persulphates, we ensured that we would 
not miss any patient sensitized to only one of the three 
persulphates [35].
Although several reports of positive SPTs with persul-
phates exist [8, 19, 21, 23], an equal amount of studies 
have failed to produce positive reactions [7, 14, 30, 31]. 
Moreover, in some patients, positive reactions are not 
reproducible over time [36].
The fact that specific IgEs to persulphates have been 
detected in only three [10, 37], out of more than 40 
reported positive SPT cases, indicates that positive 
SPT reactions are caused by nonspecific non-IgE medi-
ated histamine release. Indeed, when researchers with a 
method capable of detecting specific IgE to persulphates 
tested five patients with positive SPT reactions, they 
found that only two had demonstrable specific IgE [10], 
suggesting that the remaining positive SPT reactions 
were not mediated by IgE.
All in all, the majority of positive SPT reactions appear 
to be caused by direct histamine release rather than 
IgE-mediated mechanisms. Moreover, they have been 
reported by only a fraction of investigators, and are 
not always reproducible. Taken together, this indicates 
that SPTs cannot be applied to testing for persulphate-
induced asthma and rhinitis.
Conclusions
The new rapid SIC with potassium persulphate proved 
safe when tested in hairdressers without a history of pre-
vious serious asthmatic reactions and had a high speci-
ficity for diagnosing persulphate-induced asthma and 
rhinitis. Based on our results, neither histamine release 
nor SPTs with persulphates appear adequate in predict-
ing asthma and rhinitis caused by persulphates.
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